Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

275 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial.
Borchmann P, Ferdinandus J, Schneider G, Moccia A, Greil R, Hertzberg M, Schaub V, Hüttmann A, Keil F, Dierlamm J, Hänel M, Novak U, Meissner J, Zimmermann A, Mathas S, Zijlstra JM, Fosså A, Viardot A, Hertenstein B, Martin S, Giri P, Scholl S, Topp MS, Jung W, Vucinic V, Beck HJ, Kerkhoff A, Unger B, Rank A, Schroers R, Zum Büschenfelde CM, de Wit M, Trautmann-Grill K, Kamper P, Molin D, Kreissl S, Kaul H, von Tresckow B, Borchmann S, Behringer K, Fuchs M, Rosenwald A, Klapper W, Eich HT, Baues C, Zomas A, Hallek M, Dietlein M, Kobe C, Diehl V; German Hodgkin Study Group; Swiss Group for Clinical Cancer Research; Arbeitsgemeinschaft Medikamentöse Tumortherapie; Nordic Lymphoma Group; Australasian Leukaemia and Lymphoma Group. Borchmann P, et al. Among authors: dietlein m. Lancet. 2024 Jul 27;404(10450):341-352. doi: 10.1016/S0140-6736(24)01315-1. Epub 2024 Jul 3. Lancet. 2024. PMID: 38971175 Free article. Clinical Trial.
Involved-site Radiation Therapy is Equally Effective and Less Toxic Than Involved-field Radiation Therapy in Patients Receiving Combined Modality Treatment for Early-stage Unfavorable Hodgkin Lymphoma-An Analysis of the Randomized Phase 3 HD17 Trial of the German Hodgkin Study Group.
Rosenbrock J, Kaul H, Oertel M, Celik E, Linde P, Fan J, Eichenauer DA, Bröckelmann PJ, von Tresckow B, Kobe C, Dietlein M, Fuchs M, Borchmann P, Eich HT, Baues C. Rosenbrock J, et al. Among authors: dietlein m. Int J Radiat Oncol Biol Phys. 2024 Dec 1;120(5):1344-1352. doi: 10.1016/j.ijrobp.2024.04.015. Epub 2024 Apr 15. Int J Radiat Oncol Biol Phys. 2024. PMID: 38631539 Free article. Clinical Trial.
PET/CT Reconstruction and Its Impact on [Measures of] Metabolic Tumor Volume.
Knaup H, Weindler J, van Heek L, Voltin CA, Fuchs M, Borchmann P, Dietlein M, Kobe C, Roth K. Knaup H, et al. Among authors: dietlein m. Acad Radiol. 2024 Jul;31(7):3020-3025. doi: 10.1016/j.acra.2023.12.016. Epub 2023 Dec 27. Acad Radiol. 2024. PMID: 38155023 Free article.
Primary tumour size is a prognostic parameter in patients suffering from differentiated thyroid carcinoma with extrathyroidal growth: results of the MSDS trial.
Krämer JA, Schmid KW, Dralle H, Dietlein M, Schicha H, Lerch H, Gerss J, Frankewitsch T, Schober O, Riemann B; MSDS study group. Krämer JA, et al. Among authors: dietlein m. Eur J Endocrinol. 2010 Oct;163(4):637-44. doi: 10.1530/EJE-10-0116. Epub 2010 Jul 21. Eur J Endocrinol. 2010. PMID: 20660003 Clinical Trial.
[Guideline for Radioiodine Therapy for Benign Thyroid Diseases (6/2022 - AWMF No. 031-003)].
Dietlein M, Grünwald F, Schmidt M, Kreissl MC, Luster M; Deutsche Gesellschaft für Allgemein- und Viszeralchirurgie e. V. (DGAV); Chirurgische Arbeitsgemeinschaft Endokrinologie (CAEK) der DGAV; Deutsche Gesellschaft für Chirurgie e. V. (DGCH); Deutsche Gesellschaft für Endokrinologie e. V. (DGE). Dietlein M, et al. Nuklearmedizin. 2024 Feb;63(1):8-20. doi: 10.1055/a-2185-7885. Epub 2023 Oct 23. Nuklearmedizin. 2024. PMID: 37871629 Free article. German.
Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphoma.
Fuchs M, Jacob AS, Kaul H, Kobe C, Kuhnert G, Pabst T, Greil R, Bröckelmann PJ, Topp MS, Just M, Hertenstein B, Soekler M, Vogelhuber M, Zijlstra JM, Keller UB, Krause SW, Dührsen U, Meissner J, Viardot A, Eich HT, Baues C, Diehl V, Rosenwald A, Buehnen I, von Tresckow B, Dietlein M, Borchmann P, Engert A, Eichenauer DA. Fuchs M, et al. Among authors: dietlein m. Leukemia. 2024 Jan;38(1):160-167. doi: 10.1038/s41375-023-02064-y. Epub 2023 Oct 16. Leukemia. 2024. PMID: 37845285 Free PMC article. Clinical Trial.
275 results